Table 3. Chemotherapy agents used in treatment of metastatic pancreatic cancer (N=2,548).
| Chemotherapy | N | % |
|---|---|---|
| NCCN-approved | ||
| Capecitabine | 102 | 4.00 |
| Erlotinib | 131 | 5.14 |
| Fluorouracil | 102 | 4.00 |
| Gemcitabine | 1,080 | 42.39 |
| Oxaliplatin | 278 | 10.91 |
| Nab-Paclitaxel | 105 | 4.12 |
| Total NCCN-approved | 1,992 | 78.18 |
| Other (>10 patients treated) | ||
| Carboplatin | 21 | 0.82 |
| Cisplatin | 30 | 1.18 |
| Dexamethasone | 22 | 0.86 |
| Doxorubicin | 16 | 0.63 |
| Docetaxel | 15 | 0.59 |
| Etoposide | 25 | 0.98 |
| Sunitinib | 19 | 0.75 |
| Unknown | 30 | 1.18 |
Not listed are agents used on less than 10 patients: Bendamustine, Camptothecin, Cyclocytidine, Cyclophosphamide, Epirubicin, Everolimus, Floxuridine, Leucovorin, Lomustine, Mitomycin, Octreotide, Pemetrexed, Streptozocin, RAD001, Temozolomide, Vincristine.